Tag Archives: Economics

The $750 Pill: Corporate Greed, Excessive Regulation—or Both?

Dr. Mary Ruwart Why, you might ask, can Shkreli price his drug so high and not fear that a generic competitor will undercut him? After all, the daraprim no longer has patent protection. The answer: Turing Pharmaceuticals has a de facto monopoly, courtesy of the ever-increasing costs of gaining FDA approval, both for new drugs […]